ARTICLE | Clinical News
Hemispherx begins Phase IIb
March 7, 2001 8:00 AM UTC
HEB began a U.S. Phase IIb study of Ampligen nucleic acid antiviral agent that activates the 2-5A enzyme to treat HIV infection. The company said several hundred patients will be enrolled. ...